CN117295755A - Psd-95抑制剂及其用途 - Google Patents

Psd-95抑制剂及其用途 Download PDF

Info

Publication number
CN117295755A
CN117295755A CN202280033562.9A CN202280033562A CN117295755A CN 117295755 A CN117295755 A CN 117295755A CN 202280033562 A CN202280033562 A CN 202280033562A CN 117295755 A CN117295755 A CN 117295755A
Authority
CN
China
Prior art keywords
compound
seq
cpp
peptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280033562.9A
Other languages
English (en)
Chinese (zh)
Inventor
V·塞雷凯特
C·R·O·比奇-巴特林
K·斯特罗姆戈德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Københavns Universitet
Original Assignee
Københavns Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Københavns Universitet filed Critical Københavns Universitet
Publication of CN117295755A publication Critical patent/CN117295755A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202280033562.9A 2021-05-12 2022-05-12 Psd-95抑制剂及其用途 Pending CN117295755A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21173587 2021-05-12
EP21173587.3 2021-05-12
PCT/EP2022/062893 WO2022238530A1 (en) 2021-05-12 2022-05-12 Psd-95 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CN117295755A true CN117295755A (zh) 2023-12-26

Family

ID=75914418

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280033562.9A Pending CN117295755A (zh) 2021-05-12 2022-05-12 Psd-95抑制剂及其用途

Country Status (16)

Country Link
US (1) US20240245793A1 (https=)
EP (1) EP4337673B1 (https=)
JP (1) JP2024520234A (https=)
KR (1) KR20240007140A (https=)
CN (1) CN117295755A (https=)
AU (1) AU2022274309A1 (https=)
BR (1) BR112023021410A2 (https=)
CA (1) CA3218073A1 (https=)
ES (1) ES3040762T3 (https=)
IL (1) IL307244A (https=)
MX (1) MX2023013313A (https=)
PL (1) PL4337673T3 (https=)
SA (1) SA523451347B1 (https=)
TW (1) TW202306965A (https=)
WO (1) WO2022238530A1 (https=)
ZA (1) ZA202308712B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4706670A1 (en) * 2023-04-26 2026-03-11 Shenzhen Salubris Pharmaceuticals Co., Ltd. Psd-95 domain inhibitor, and preparation method therefor and use thereof
JP7723457B2 (ja) * 2023-07-03 2025-08-14 メスキュージェナシス株式会社 細胞膜透過性を有するペプチドおよびそのスクリーニング方法
CN117164725B (zh) * 2023-09-07 2024-05-10 湖南中晟全肽生物科技股份有限公司 一种突触后密度蛋白-95抑制剂多肽
CN119569824A (zh) * 2023-09-07 2025-03-07 湖南中晟全肽生物科技股份有限公司 作为神经保护剂的药用化合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010004003A2 (en) 2008-07-09 2010-01-14 University Of Copenhagen Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction
ES2544573T3 (es) 2011-05-13 2015-09-01 Københavns Universitet (University Of Copenhagen) Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor
WO2020083905A1 (en) * 2018-10-22 2020-04-30 University Of Copenhagen Inhibitors of pick1 and uses thereof

Also Published As

Publication number Publication date
ZA202308712B (en) 2025-02-26
PL4337673T3 (pl) 2026-01-05
KR20240007140A (ko) 2024-01-16
AU2022274309A9 (en) 2024-01-25
US20240245793A1 (en) 2024-07-25
ES3040762T3 (en) 2025-11-04
EP4337673A1 (en) 2024-03-20
JP2024520234A (ja) 2024-05-23
CA3218073A1 (en) 2022-11-17
MX2023013313A (es) 2023-12-04
SA523451347B1 (ar) 2024-08-27
BR112023021410A2 (pt) 2023-12-19
EP4337673B1 (en) 2025-07-09
TW202306965A (zh) 2023-02-16
AU2022274309A1 (en) 2023-09-28
WO2022238530A1 (en) 2022-11-17
EP4337673C0 (en) 2025-07-09
IL307244A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
CN117295755A (zh) Psd-95抑制剂及其用途
JP6480865B2 (ja) 新規なα４β７ペプチド二量体拮抗薬
US6001961A (en) Cyclic adhesion inhibitors
KR102787208B1 (ko) α4β7 인테그린 티오에테르 펩티드 길항제
CN101678213B (zh) 环肽cxcr4拮抗剂
JP6633523B2 (ja) Ｐｓｄ−９５の二量体阻害剤脂肪酸誘導体
KR20160011625A (ko) 새로운 α4β7 펩타이드 이량체 길항제들
HUP0201925A2 (en) Cyclic peptide derivatives as inhibitors of integrin alphavbeta6 and their use
AU2021309548A1 (en) Inhibitors of complement factor C3 and their medical uses
JP2599947B2 (ja) ペプチド化合物
EP0555328A1 (en) Platelet aggregation inhibitors
US20170246311A1 (en) Peptides for binding alternatively activated macrophages
CA2937032C (en) Activated neurotensin molecules and the uses thereof
HK40108323A (en) Psd-95 inhibitors and uses thereof
HK40108323B (en) Psd-95 inhibitors and uses thereof
HUP0201729A2 (en) Inhibitors of the integrin alpha v betha 6
US8076453B2 (en) Kinin B1 receptor peptide agonists and uses thereof
JP2024536413A (ja) 二環式ペプチドリガンド薬物コンジュゲート
HK40112064A (zh) Crf2受体激动剂及其在治疗中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination